| Annual Financials | Mar 2024 | Mar 2025 | Jan 2026 |
| Revenue | 23.96 | 45.24 | 41.84 |
| Expenses | 21.43 | 36.17 | 34.06 |
| Other Income | 0.41 | 0.73 | 0.11 |
| Total Revenue | 24.37 | 45.97 | 41.94 |
| Profit Before Tax | 2.95 | 9.80 | 7.88 |
| Net Profit | 2.14 | 7.23 | 5.74 |
Avience Biomedicals
Avience Biomedicals IPO
₹2,35,200
43.16 xOver-subscribedBidding Dates 18 Jun, 26 -22 Jun, 26
Min Investment ₹2,35,200
Lot Size600
Price Range ₹196 – ₹208
Issue Size ₹30.24 Cr.
Download Doc
IPO Subscription Details
Retail Subscription Details
57.64 x
Non-Institutional Buyers (sHNI)
66.46 x
Non-Institutional Buyers (bHNI)
66.52 x
Qualified Institutional Buyers (QIB)
0.02 x
Total43.16 x
43.16 x IPO Timeline
IPO Offer Start
18 Jun,26
IPO Offer Ends
22 Jun,26
Allotment Finalisation
23 Jun,26
Refund Initiation
24 Jun,26
Listing of Shares
25 Jun,26
IPO Analysis
Strengths
The company offers an extensive portfolio of IVD Rapid Tests and advanced medical devices designed to address healthcare challenges, including high-performance diagnostic tests for infectious diseases and haematology and biochemistry analyzers.
The company's products adhere to rigorous international quality and safety standards, including ISO 13485, ISO 9001, CE marking, and GMP (Good Manufacturing Practices) certifications.
The company has built a strong reputation for reliability, quality standards, and exceptional customer satisfaction both within domestic market and on the global stage, gaining confidence of healthcare professionals.
Risks
The company operates in a highly regulated pharmaceutical industry and must comply with regulatory requirements across multiple jurisdictions including India, Dubai, Ethiopia, Ghana, Somalia, Nepal and Zambia. Failure to comply could result in show cause notices, warning letters, civil or criminal penalties, suspension or withdrawal of regulatory approvals, product recalls, and loss of contracts.
The company is dependent on certain customers for a substantial portion of revenue, with top 10 customers contributing 46.44% of revenues in the period ended January 31, 2026. Loss of major customers or significant reduction in business from key customers could materially affect business operations and financial performance.
The company relies on suppliers for medical devices and equipment for trading goods and faces risks in sourcing raw materials from third parties for manufacturing. Any disruption in supply could adversely impact business operations, with the company having experienced some disruptions during COVID period.
Objectives
The company intends to establish a new manufacturing facility to expand its production capacity for IVD products and medical devices. The facility will house advanced machinery and technology to enhance production capabilities, improve product quality, and achieve WHO compliance for global market access.
The company plans to utilize funds to meet increased working capital requirements driven by business expansion, higher inventory levels, trade receivables growth, and operational scaling to support the new manufacturing facility and product portfolio expansion.
The company intends to deploy funds for strategic initiatives, strengthening marketing network and capability, brand building exercises, meeting exigencies, and other expenditures in the ordinary course of business as approved by the Board, subject to regulatory compliance.
Yearly Financial Results
Balance Sheet
| Balance Sheet | Mar 2024 | Mar 2025 | Jan 2026 |
| Total Assets | 34.65 | 56.52 | 66.07 |
| Current Assets | 23.05 | 37.17 | 38.73 |
| Fixed Assets | 11.60 | 19.35 | 27.35 |
| Total Equity & Liabilities | 34.65 | 56.52 | 66.07 |
| Total Liabilities | 28.44 | 33.75 | 37.56 |
| Current Liabilities | 20.82 | 23.51 | 25.18 |
| Non Current Liabilities | 7.62 | 10.24 | 12.38 |
| Total Equity | 6.21 | 22.78 | 28.52 |
Cash Flow
| Cash Flow | Mar 2024 | Mar 2025 | Jan 2026 |
| Net Cash Flow | -0.08 | 4.05 | -3.19 |
| Investing Activities | -4.03 | -8.81 | -9.04 |
| Operating Activities | 0.98 | 3.61 | 2.78 |
| Financing Activities | 2.97 | 9.25 | 3.07 |
About Avience Biomedicals
Avience Biomedicals Limited is a medical consumable company established in 2019 that manufactures In Vitro Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India. The company operates in both B2B and B2C markets, serving pathology labs, microbiology labs, hospitals, and research centers nationwide as well as overseas. The...more
Website
Managing DirectorDharam Deo Choudhary
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
